pharma · Dravet Syndrome · Dravet syndrome · STOK
Stoke Therapeutics
Stoke Therapeutics is a pharma organization headquartered in Bedford, USA. It trades on NYSE under ticker STOK. Primary therapeutic focus areas include Dravet Syndrome, Dravet syndrome, Autosomal Dominant Optic Atrophy,
Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bedford, USA
- Founded
- 2017
- Employees
- 205
- Programs
- 8
- Drugs
- 4
- Patents
- 14
Milrinone
Phase 2 · small molecule · Valvular Stenosis
Milrinone for Valvular Stenosis is a Phase 2 program (small_molecule) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 08-1004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Stoke Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Valvular Stenosis
- Status
- completed
- Trials
- 1